GlassScriptPhysician profile
Romy Elias Abboud
NPI 1720660335
$8,399.34
in general payments reported to CMS, 2019-2025
30 companies · $2,117 in 2025
The $2,117 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $331 · 2022: $2,520 · 2023: $1,587 · 2024: $1,845 · 2025: $2,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,921 · Education: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,921.13 |
| Education | $627.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,100.28 | 2021-2025 | Rinvoq, Skyrizi, Humira |
| Sun Pharmaceutical Industries INC. | $716.51 | 2021-2025 | Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $692.28 | 2022-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $625.11 | 2022-2025 | |
| Incyte Corporation | $580.79 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $512.57 | 2022-2025 | Dupixent |
| Genzyme Corporation | $412.56 | 2021-2024 | |
| Lilly USA, LLC | $381.97 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $366.36 | 2022-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $354.86 | 2022-2025 | Nemluvio |
| Ucb, INC. | $288.59 | 2024-2025 | Bimzelx |
| Pfizer INC. | $286.35 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $191.16 | 2021-2022 | |
| Novo Nordisk INC | $125.00 | 2021 | |
| Mallinckrodt Hospital Products INC. | $105.64 | 2022-2025 | Acthar |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $100.75 | 2022-2024 | Otezla, Tavneos |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Janssen Scientific Affairs, LLC | $85.34 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.37 | 2024 | Spevigo, Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $68.35 | 2022-2024 | Sotyktu |
| Almirall LLC | $45.20 | 2023 | Seysara, Klisyri |
| Fresenius Kabi USA, LLC | $40.55 | 2023 | Idacio |
| Journey Medical Corporation | $28.84 | 2022 | |
| Biofrontera INC. | $28.01 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Botanix Sb INC | $18.09 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $17.84 | 2023 | |
| Dermavant Sciences, INC. | $17.40 | 2023 | Vtama |
| Convatec INC. | $14.76 | 2024 | |
| Heron Therapeutics, INC. | $12.57 | 2021 | |
| Organon LLC | $11.25 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romy Abboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.